Clinical Trials Insight: 700027119
Phase of Trial: Phase II
Latest Information Update: 13 May 2008
At a glance
- Drugs Verpasep caltespen (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors Nventa Biopharmaceuticals Corporation
- 13 May 2008 Nventa have completed the significant design elements of this trial, according to an Nventa media release.
- 24 Apr 2008 Nventa are currently finalising the trial design and plan to initiate enrolment by mid-2008.
- 24 Sep 2007 New trial record.